WALTHAM, Mass.–Â Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS), a next-generation robotics company transforming the field of surgery, today announced the appointment of Stephen From as Chief Executive Officer and member of the Board of Directors, effective August 7, 2025. Co-Founder and current CEO Adam Sachs will transition to the role of President while continuing to serve on the Board and the executive leadership team.
Stephen From brings more than two decades of experience in the healthcare and financial sectors. He most recently served as CEO of Aruna Bio, where he led the strategic direction and clinical advancement of its proprietary neural exosome platform. Previously, From was President and CEO of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), formerly EyeGate Pharmaceuticals, from October 2005 to February 2021, and then served as Executive Chairman until January 2022. During his tenure, he guided the company through its IPO and executed multiple acquisitions and licensing deals in the ophthalmic therapeutics space.
Earlier in his career, From was CFO of Centelion SAS, a biotechnology subsidiary of Sanofi‑Aventis, and held investment banking roles at Bank of America Securities and Robertson Stephens, specializing in life sciences. He holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University.
“I’m honored to join Vicarious Surgical at this pivotal stage of its evolution,” said From. “The company’s technology represents a major leap forward in surgical innovation with the potential to significantly improve patient outcomes worldwide. I look forward to working closely with the talented team and Board to execute on our strategic priorities and unlock the full potential of this groundbreaking platform.”
Reflecting on the transition, Adam Sachs said, “It has been an incredible journey leading Vicarious Surgical from its founding through pre-clinical testing. I’m proud of everything we’ve achieved so far. As I step into the role of President, I’m excited to welcome Stephen as our new CEO. His leadership and experience are exactly what we need at this critical juncture, and I look forward to partnering with him to continue advancing our mission to transform surgical care through robotics.”
In connection with From’s appointment, and in accordance with New York Stock Exchange Listed Company Manual Rule 303A.08 (the “Inducement Rule”), the company will grant him a stock option award as a material inducement to join Vicarious Surgical. Approved by the Board and Compensation Committee, the grant will be effective August 7, 2025.
The option will allow Mr. From to purchase up to 297,600 shares of the company’s Class A common stock at an exercise price equal to the closing price on the grant date. The option will vest over four years: 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service and potential acceleration under certain conditions. The award will be issued outside of the company’s existing 2021 Equity Incentive Plan, though its terms will generally align with the plan’s provisions, except where required by the Inducement Rule.
